Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients
Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive ofĀ multiple sclerosis (MS), a condition known as radiologically isolated syndrome. The Phase 4 study (NCT04877457) aims to evaluate whether short-term treatment with Ocrevus can…